Adnexus Therapeutics, Inc.
Adnexus Therapeutics, Inc. engages in the discovery, development, and commercialization of Adnectins biologics/medicines in the United States. The company’s product candidates include Angiocept/CT-322, an anti-angiogenesis agent for treating cancer that blocks the VEGFR-2 pathway; and other Adnectin therapies for the treatment of oncology, immunology, and cardiovascular diseases. Adnexus Therapeutics, Inc. was formerly known as Compound Therapeutics, Inc. and changed its name to Adnexus Therapeutics, Inc. in June 2006. The company was founded in 2002 and is headquartered in Waltham, Massachusetts. As of October 19, 2007, Adnexus Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Co.
Contact Details
Office Address
Adnexus Therapeutics, Inc.
100 Beaver Street
Waltham, MA, USA 02453
Phone: (781) 891-3745
Fax: (781) 891-3796
Executives
President
John B. Edwards
Financial Consultant and Interim Chief Financial Officer
Lorin J. (Jeff) Randall